Ramipril 10 mg/Day Prevention

Inclusion criteria

• History of coronary artery disease,
• Stroke
• Stable heart failure
• Peripheral vascular disease, or diabetes with at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low high-density lipoprotein cholesterol levels, cigarette smoking, or documented microalbuminuria).

Exclusion criteria

• Non stabilized or NYHA grade IV heart failure patients
• Hemodynamically significant primary valvular or outflow tract obstruction (eg. mitral valve stenosis, asymmetric septal hypertrophy, malfunctioning prosthetic valve)
• Constrictive pericarditis.
• Complex congenital heart disease.
• Syncopal episodes presumed to be due to uncontrolled life-threatening arrhythmias (asymptomatic cardiac arrhythmias including ventricular tachycardia are not an exclusion criterion).
• Planned cardiac surgery or angioplasty within 3 months (patient may be reconsidered for the trial after the procedure).
• Cor pulmonale.
• Heart transplant recipient.
• Significant renal disease defined as:

• Renal artery stenosis;
• Creatine clearance <0.6 ml/second or serum creatinine≥ 200 mEq/L (≥2.26 mg/dl)
• Overt nephropathy: ≥1 plus proteinuria on dipstick or urinary albumin excretion > 200 micrograms/minute (300 mg/24 hrs)
• Hyperkalemia; K>5.5 mEq/L.
• Patient is simultaneously taking another experimental drug.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.